CVRx Inc (NAS:CVRX)

$ 15.31 0.01 (0.07%) Market Cap: 371.48 Mil Enterprise Value: 321.76 Mil PE Ratio: 0 PB Ratio: 5.69 GF Score: 55/100

Q3 2024 CVRx Inc Earnings Call Transcript
Oct 29, 2024

$10.74 (+4.37%)

Earnings
Q2 2024 CVRx Inc Earnings Call Transcript
Jul 29, 2024

$9.27 (-3.54%)

Earnings
Q1 2024 CVRx Inc Earnings Call Transcript
Apr 30, 2024

$15.51 (+1.51%)

Earnings
Q4 2023 CVRx Inc Earnings Call Transcript
Jan 25, 2024

$29.2 (+5.72%)

Earnings
CVRx Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Q3 2023 CVRx Inc Earnings Call Transcript
Oct 26, 2023

$12.84 (-3.53%)

Earnings
Q2 2023 CVRx Inc Earnings Call Transcript
Jul 25, 2023

$16.94 (+0.77%)

Earnings
CVRx Inc at William Blair Growth Stock Conference Transcript
Jun 08, 2023
Q1 2023 CVRx Inc Earnings Call Transcript
Apr 27, 2023

$9.48 (+0.96%)

Earnings
CVRx Inc To Discuss Preliminary Results of the BeAT-HF Post-Market Clinical Trial Call Transcript
Mar 21, 2023
CVRx Inc To Discuss The Preliminary Results Of The BeAT-HF Call Transcript
Feb 21, 2023
Q4 2022 CVRx Inc Earnings Call Transcript
Jan 26, 2023

$14.37 (+0.14%)

Earnings
CVRx Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Q3 2022 CVRx Inc Earnings Call Transcript
Nov 01, 2022

$10.24 (+1.54%)

Earnings
Q2 2022 CVRx Inc Earnings Call Transcript
Jul 28, 2022

$7.55 (+4.43%)

Earnings
Q1 2022 CVRx Inc Earnings Call Transcript
Apr 25, 2022

$4.9 (+1.03%)

Earnings
Q4 2021 CVRx Inc Earnings Call Transcript
Feb 15, 2022

$8.62 (+7.62%)

Earnings
CVRx Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2022

CVRx Inc To Discuss Preliminary Results of the BeAT-HF Post-Market Clinical Trial Call Transcript

Mar 21, 2023 / 08:30PM GMT

Release Date Price: $9.47 (-3.66%)

Transcript

Operator

Greetings, and welcome to CVRx shares preliminary results of the BeAT-HF post-market clinical trials. (Operator Instructions)

As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Nadim Yared, President and Chief Executive Officer. Thank you. You may begin.

Nadim Yared

CVRx, Inc. - CEO, President & Director

Good afternoon, and thank you for joining us today for this important update. I am excited to share with you the preliminary top line results of the post-market phase of our BeAT-HF trial, as presented at the Technology and Heart Failure Therapeutics Conference or THT in Boston today by Dr. Michael Zile, Chair of the Executive Steering Committee of the trial.

Before we go further, I need to state that the remarks today will contain forward-looking statements including statements about expected product developments, regulatory matters and business impacts. The statements are based on plans and expectations as of today, which may change over time.

In addition, actual results could

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.